We are live on ! Find out more
TECP

Trails Edge Capital Partners Portfolio holdings

AUM $630M
This Fund
S&P 500
This Quarter Est. Return
+55.36%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$405M
AUM Growth
–
Cap. Flow
+$350M
Cap. Flow %
86.44%
Top 10 Hldgs %
68.52%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$33.9M
2
PCVX icon
Vaxcyte
PCVX
+$33M
3
DFTX icon
Definium Therapeutics
DFTX
+$31.8M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$25.1M
5
NRIX icon
Nurix Therapeutics
NRIX
+$25M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$3.41B
$37.9M 9.37%
+1,419,406
New +$33.9M
2025 Q4
0 quarters
DFTX icon
2
Definium Therapeutics
DFTX
$4.96B
$34.4M 8.5%
+2,568,110
New +$31.8M
2025 Q4
0 quarters
PCVX icon
3
Vaxcyte
PCVX
$10.6B
$34M 8.41%
+737,470
New +$33M
2025 Q4
0 quarters
NRIX icon
4
Nurix Therapeutics
NRIX
$2.32B
$33.1M 8.17%
+1,743,220
New +$25M
2025 Q4
0 quarters
LBRX icon
5
LB Pharmaceuticals
LBRX
$1.2B
$31.1M 7.68%
+1,395,608
New +$24.4M
2025 Q4
0 quarters
XENE icon
6
Xenon Pharmaceuticals
XENE
$3.53B
$26.8M 6.61%
+597,092
New +$25.1M
2025 Q4
0 quarters
IMCR icon
7
Immunocore
IMCR
$1.51B
$23.7M 5.85%
+682,597
New +$24.1M
2025 Q4
0 quarters
RCUS icon
8
Arcus Biosciences
RCUS
$3.11B
$21.8M 5.4%
+916,313
New +$18.7M
2025 Q4
0 quarters
TYRA icon
9
Tyra Biosciences
TYRA
$1.37B
$18.4M 4.55%
+700,000
New +$12.9M
2025 Q4
0 quarters
NGNE icon
10
Neurogene
NGNE
$528M
$16.2M 4%
+785,000
New +$19.5M
2025 Q4
0 quarters
FOLD icon
11
DELISTED
Amicus Therapeutics
FOLD
$14.9M 3.67%
+1,043,313
New +$10.2M
2025 Q4
0 quarters
APGE icon
12
DELISTED
Apogee Therapeutics
APGE
$14.5M 3.58%
+192,000
New +$12.1M
2025 Q4
0 quarters
IKT icon
13
Inhibikase Therapeutics
IKT
$275M
$12.7M 3.13%
+6,178,124
New +$9.83M
2025 Q4
0 quarters
IVA icon
14
Inventiva
IVA
$747M
$12.4M 3.05%
+2,657,997
New +$12.4M
2025 Q4
0 quarters
CAMP icon
15
CAMP4 Therapeutics
CAMP
$237M
$12.2M 3%
+1,983,986
New +$8.44M
2025 Q4
0 quarters
TERN icon
16
DELISTED
Terns Pharmaceuticals
TERN
$12.1M 2.99%
+300,000
New +$6.93M
2025 Q4
0 quarters
XFOR icon
17
X4 Pharmaceuticals
XFOR
$289M
$10.3M 2.54%
+2,571,478
New +$9.34M
2025 Q4
0 quarters
MBX icon
18
MBX Biosciences
MBX
$2.56B
$9.94M 2.46%
+315,158
New +$7.65M
2025 Q4
0 quarters
VTVT icon
19
vTv Therapeutics
VTVT
$123M
$9.24M 2.28%
+231,000
New +$6.43M
2025 Q4
0 quarters
CMPX icon
20
Compass Therapeutics
CMPX
$179M
$7.6M 1.88%
+1,415,273
New +$6.54M
2025 Q4
0 quarters
IMVT icon
21
Immunovant
IMVT
$6.29B
$6.1M 1.51%
+240,165
New +$5.36M
2025 Q4
0 quarters
ELVN icon
22
Enliven Therapeutics
ELVN
$3B
$3.07M 0.76%
+199,306
New +$3.97M
2025 Q4
0 quarters
MIRM icon
23
Mirum Pharmaceuticals
MIRM
$5.58B
$2.52M 0.62%
+31,862
New +$2.29M
2025 Q4
0 quarters

Similar funds

SJIC
St. James Investment Company Southlake, Texas $630M AUM 12.48% 1-Year Est. Return
SFO
Stenger Family Office Naperville, Illinois $629M AUM 25.67% 1-Year Est. Return
PPC
Park Place Capital Homewood, Alabama $629M AUM 18.27% 1-Year Est. Return
ACGA
Atlanta Consulting Group Advisors Atlanta, Georgia $631M AUM 22.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
MC
Machina Capital Paris, France $631M AUM 11.37% 1-Year Est. Return
GPTE
Generali Powszechne Towarzystwo Emerytalne Warsaw, Poland $631M AUM 32.98% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Trails Edge Capital Partners's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Trails Edge Capital Partners, which disclosed 23 positions worth $405M. Its ten largest holdings account for 69% of the portfolio.

Its largest position is Acadia Pharmaceuticals: 1,419,406 shares worth $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Trails Edge Capital Partners's largest Q4 2025 buy was Acadia Pharmaceuticals: 1,419,406 shares worth $37.9M.
  • Trails Edge Capital Partners's ten largest holdings make up 69% of its $405M portfolio in Q4 2025.
  • Trails Edge Capital Partners disclosed 23 positions in Q4 2025, its first 13F filing on record.

Based on Trails Edge Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.